Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach

Affiliations

¹ Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. valentina.giunchi2@unibo.it.
² Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
³ Pfizer Inc, New York, NY, USA.

^# Contributed equally.

Editorial

Valentina Giunchi et al. Drug Saf. 2023 Oct.

. 2023 Oct;46(10):921-926.

doi: 10.1007/s40264-023-01345-w. Epub 2023 Aug 31.

¹ Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. valentina.giunchi2@unibo.it.
² Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
³ Pfizer Inc, New York, NY, USA.

^# Contributed equally.

No abstract available

References

1. Centre UM. About VigiBase [Internet]. https://who-umc.org/vigibase/ . Accessed 13 May 2023.
1. Research C for DE and. FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA [Internet]. 2021. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-repor... . Accessed 13 May 2023.
1. Hauben M, Reich L, DeMicco J, Kim K. “Extreme duplication” in the US FDA Adverse Events Reporting System database. Drug Saf. 2007;30:551–4. - DOI - PubMed
1. Hung E, Hauben M, Essex H, Zou C, Bright S. More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching. Pharmacoepidemiol Drug Saf. 2023;32:387–91. - DOI - PubMed
1. MedDRA [Internet]. https://www.meddra.org/ . Accessed 4 Feb 2023.